Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 8, Issue , 2017, Pages 131-138

  Carro, Eva ^a,b   Bartolomé, Fernando ^a,b   Bermejo Pareja, Félix ^a,b,c   Villarejo Galende, Alberto ^a,b,c   Molina, José Antonio ^a,b,c,d   Ortiz, Pablo ^b,c   Calero, Miguel ^a,e,f   Rabano, Alberto ^e   Cantero, José Luis ^a,g   Orive, Gorka ^h,i  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b Universidad Complutense   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^h UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

ⁱ BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Alzheimer's disease; Dementia; Diagnosis; Lactoferrin; Mild cognitive impairment; Noninvasive biomarkers; Saliva

Indexed keywords

BIOLOGICAL MARKER; LACTOFERRIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MASS SPECTROMETRY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NON INVASIVE PROCEDURE; PROTEIN EXPRESSION; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

EID: 85020392027     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2017.04.002     Document Type: Article

References (37)

1. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
2. Blennow, K., Zetterberg, H., Understanding biomarkers of neurodegeneration: ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med 21 (2015), 217–219.
3. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H.C., Riemenschneider, M., De Deyn, P.P., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999), 1555–1562.
4. Small, S.A., Perera, G.M., DeLaPaz, R., Mayeux, R., Stern, Y., Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 45 (1999), 466–472.
5. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
6. Franceschi, C., Bonafè, M., Valensin, S., Paolisso, G., Yashin, A.I., Monti, D., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908 (2000), 244–254.
7. Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J.A., Carro, E., Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurol, 10, 2010, 108.
8. Shi, M., Sui, Y.T., Peskind, E.R., Li, G., Hwang, H., Devic, I., et al. Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis 27 (2011), 299–305.
9. Devic, I., Hwang, H., Edgar, J.S., Izutsu, K., Presland, R., Pan, C., et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain, 134, 2011, e178.
10. Kamer, A.R., Craig, R.G., Dasanayake, A.P., Brys, M., Glodzik-Sobanska, L., de Leon, M.J., Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement 4 (2008), 242–250.
11. Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73 (2009), 768–774.
12. Iwashyna, T.J., Ely, E.W., Smith, D.M., Langa, K.M., Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304 (2010), 1787–1794.
13. Hill, J.M., Clement, C., Pogue, A.I., Bhattacharjee, S., Zhao, Y., Lukiw, W.J., Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Front Aging Neurosci, 6, 2014, 127.
14. van der Strate, B.W., Beljaars, L., Molema, G., Harmsen, M.C., Meijer, D.K., Antiviral activities of lactoferrin. Antiviral Res 52 (2001), 225–239.
15. Beljaars, L., van der Strate, B.W., Bakker, H.I., Reker-Smit, C., van Loenen-Weemaes, A.M., Wiegmans, F.C., et al. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res 63 (2004), 197–208.
16. Orsi, N., The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17 (2004), 189–196.
17. Gifford, J.L., Hunter, H.N., Vogel, H.J., Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62 (2005), 2588–2598.
18. Valenti, P., Catizone, A., Pantanella, F., Frioni, A., Natalizi, T., Tendini, M., et al. Lactoferrin decreases inflammatory response by cystic fibrosis bronchial cells invaded with Burkholderia cenocepacia iron-modulated biofilm. Int J Immunopathol Pharmacol 24 (2011), 1057–1068.
19. Berlutti, F., Schippa, S., Morea, C., Sarli, S., Perfetto, B., Donnarumma, G., et al. Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. Biochem Cell Biol 84 (2006), 351–357.
20. Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., Terasaki, T., Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem 103 (2007), 2482–2490.
21. Jaeger, S., Pietrzik, C.U., Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 5 (2008), 15–25.
22. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
23. Petersen, R.C., Mild cognitive impairment as a diagnostic entity. J Intern Med 256 (2004), 183–194.
24. Gelb, D.J., Oliver, E., Gilman, S., Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999), 33–39.
25. Calne, D.B., Snow, B.J., Lee, C., Criteria for diagnosing Parkinson's disease. Ann Neurol 32 (1992), S125–S127.
26. Aagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., et al. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J 27 (2013), 1012–1022.
27. Faucheux, B.A., Nillesse, N., Damier, P., Spik, G., Mouatt-Prigent, A., Pierce, A., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A 92 (1995), 9603–9607.
28. Leveugle, B., Faucheux, B.A., Bouras, C., Nillesse, N., Spik, G., Hirsch, E.C., et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91 (1996), 566–572.
29. Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
30. Dubois, B., Hampel, H., Feldman, H.H., Scheltens, P., Aisen, P., Andrieu, S., et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12 (2016), 292–323.
31. Knopman, D.S., Rocca, W.A., Cha, R.H., Edland, S.D., Kokmen, E., Incidence of vascular dementia in Rochester, Minn, 1985-1989. Arch Neurol 59 (2002), 1605–1610.
32. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 (2010), 119–128.
33. Legrand, D., Elass, E., Carpentier, M., Mazurier, J., Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62 (2005), 2549–2559.
34. Welling, M.M., Nabuurs, R.J., van der Weerd, L., Potential role of antimicrobial peptides in the early onset of Alzheimer's disease. Alzheimers Dement 11 (2015), 51–57.
35. Alonso, R., Pisa, D., Marina, A.I., Morato, E., Rábano, A., Carrasco, L., Fungal infection in patients with Alzheimer's disease. J Alzheimers Dis 41 (2014), 301–311.
36. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20 (2014), 415–418.
37. Roe, C.M., Fagan, A.M., Williams, M.M., Ghoshal, N., Aeschleman, M., Grant, E.A., et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76 (2011), 501–510.